Industry & Business

Bristol-Myers Squibb to sell Swords manufacturing facility to SK Biotek Co., Ltd.

 Breaking News
  • Fine Grain Property acquires 60,000 square feet office development in Cork Airport Business Park New Year, new acquisition! Fine Grain Property is delighted to announce it has acquired a 60,000 square feet office development in Cork Airport Business Park. Plans are already afoot to carry out some important improvements to the Building that will benefit its existing tenants, including Aviva, Aon Hewitt, JLT and Genesis. In addition, a significant [...]...
  • Irish Technology Sector Has Overtaken Agriculture With 130,000 people now employed, the technology sector has overtaken agriculture as Ireland’s largest industry, according to Ken Finnegan (pictured above), formerly Chief Technology and Research Advisor for IDA Technology Ireland and now Director of Technology & Innovation for the about to be opened Harbour Innovation Campus at Dún Laoghaire. About 15,000 of these tech [...]...
  • 2018 Research and Innovation Conference & Exhibition Provides Insight into the R&D and Innovation Ecosystem in Ireland Designed to foster collaboration between industry, academia and government agencies, the 2018 Research and Innovation Conference & Exhibition attracted over 1,000 visitors from across the major industrial sectors in Ireland to the Citywest Hotel, Dublin, on Wednesday, March 14th. The visitors who braved the inclement weather were able to meet with the key organisations that are [...]...
  • Dunnes Stores Comes Out on Top of a Growing Grocery Market The latest grocery market share figures from Kantar Worldpanel in Ireland, for the 12 weeks ending 25 February 2018, show continued positive momentum among Irish supermarkets, with growth hitting 3.9%. David Berry, director at Kantar Worldpanel, comments: “Shoppers have spent an additional €96 million on groceries over the latest 12 weeks compared to last year and two [...]...
  • New Irish Peer-to-peer Energy Trading Research Project Using Blockchain Technology Imagine a future where Irish consumers will be able to gift or sell their solar power across their neighbourhood as well as sharing and managing their own electricity in a myriad of new ways. EnerPort, a new project launched at the recent International Energy Research Centre (IERC) Annual Conference, aims to accelerate peer-to-peer energy trading [...]...

Bristol-Myers Squibb to sell Swords manufacturing facility to SK Biotek Co., Ltd.

Bristol-Myers Squibb to sell Swords manufacturing facility to SK Biotek Co., Ltd.
June 20
09:00 2017

IDA Ireland has welcomed the joint-announcement by Bristol-Myers Squibb and South Korean company SK Biotek Co., Ltd of agreement for SK Biotek to acquire Bristol-Myers Squibb’s Active Pharmaceutical Ingredients (API) Manufacturing Facility in Swords, Co Dublin.

The announcement confirms that the two companies have signed a definitive purchase agreement for Bristol-Myers Squibb to sell its small molecule active pharmaceutical ingredient manufacturing facility in Swords to SK Biotek, a wholly-owned subsidiary of SK Holdings, based in Seoul, South Korea. All jobs on the Swords site dedicated to API Operations will transition to SK Biotek.  The companies intend to complete the deal by the fourth quarter 2017, at which time SK Biotek will continue to manufacture the current portfolio of small molecule pharmaceutical products at the site.

The Swords facility currently manufactures active pharmaceutical ingredients (APIs) for a number of medicines including Bristol-Myers Squibb’s and Pfizer’s Eliquis. Through the years, the site has produced medicines that have helped millions of people in the fight against serious diseases such as cancer, cardiovascular disease, hepatitis, HIV/AIDS and psychiatric disorders. SK Biotek will operate the plant as a stand-alone Contract Development Manufacturing Organization (CDMO), and intends to add marketing, research and development (R&D) talent, and invest in upgrades to bring additional capacity to the site.

Bristol-Myers Squibb and SK Biotek anticipate that the transaction will close during the fourth quarter of 2017. Closing of the transaction is subject to SK Biotek’s receipt of certain environmental permits in addition to other customary closing conditions. The transaction has been approved by the boards of directors of both companies.

Speaking of the acquisition Junku Park Ph. D., chief executive officer of SK Biotek, commented “This transaction is an important step to achieve our goal of becoming a leading global CDMO. It allows us to enhance technological and manufacturing capacity and build long-term partnerships with existing and new customers. We have chosen to invest in Ireland because of the welcoming business environment and the exceptionally talented workforce, and we look forward to growing our presence in Swords in the coming years.  We are very pleased to welcome the Swords facility to SK Biotek.”

Lou Schmukler, president, Global Product Development & Supply, Bristol-Myers Squibb  said; “We value our partnership with SK Biotek and believe today’s agreement will continue the vital role the Swords facility plays for its employees, the community and patients.

Today’s agreement is an important step in the ongoing evolution of our manufacturing network to support the company’s innovative portfolio. Our continued investment in Ireland is critical for our ability to deliver transformational medicines to patients, both through the increased biologics capabilities we are building in Cruiserath and our ongoing commercial and business presence in Dublin.”

SK Biotek and Bristol-Myers Squibb have an established relationship in pharmaceutical manufacturing and supply. SK Biotek has been a supplier to Bristol-Myers Squibb for 10 years, and a key producer of commercial API starting materials and chemical intermediates.  With state of the art R&D facilities, multi-purpose manufacturing plants and a deep foundation in manufacturing technologies, SK has provided a high degree of flexibility and quality service to Bristol-Myers Squibb and continues to be a trusted partner from early phase development through to commercial production.

Commenting on the announcement CEO of IDA Ireland Martin Shanahan said: “I am delighted to welcome the South Korean company SK Biotek to Ireland. Great credit is acknowledged to both companies for having achieved an acquisition agreement which enables continuity of active pharmaceutical ingredients production and protects jobs on a site which has been involved in pharmaceuticals production for over 50-years. Ireland prides itself in delivering manufacturing excellence in the pharma industry and is home to nine of the ten top global pharmaceutical companies. I wish SK Biotek every success as they further develop the Swords facility in Dublin.”

About Author



Related Articles

New Subscriber

Subscribe Here


National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories

Upcoming Events

  • No upcoming events
AEC v1.0.4